Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 282 participants.

Also called NCT01279590

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 282 participants (enrolled count) (from the registry)
Sponsor
Furiex Pharmaceuticals, Inc (from the registry)
Registry
  • NCT NCT01279590
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01279590. Randomized; quadruple masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2011-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
Condition
Myalgia
Condition
Hypercholesterolemia
Condition
Hyperlipidemia
Intervention (Drug)
PPD10558
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Placebo
Lead sponsor
Furiex Pharmaceuticals, Inc (class: industry)

Record details

Record id
cardio:ct-nct01279590
Content hash
7ad980993cd2208e6049798891ca8d4a9a66a74be3e0fccfd0658b867a3e24e6